证券代码：301367 证券简称：瑞迈特 公告编号：2025-044 北京瑞迈特医疗科技股份有限公司 关于持股5%以上股东及其一致行动人 减持股份的预披露公告 公司股东能金有限公司及其一致行动人广州市金垣创业投资合伙企业（有限 合伙）、珠海合晅投资中心（有限合伙）及其一致行动人上海盛旻创业投资合伙 企业（有限合伙）和南京合灏创业投资企业（有限合伙）保证向本公司提供的信 息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、合计持有本公司股份 5,234,120 股（占本公司总股本比例 5.84%）的股东 能金有限公司及其一致行动人广州市金垣创业投资合伙企业（有限合伙）计划在 自本减持计划公告之日起 15 个交易日后的 3 个月内以集中竞价方式或大宗交易 方式减持本公司股份累计不超过 888,325 股，占本公司总股本比例 1%（总股本 已剔除公司回购专用账户中的股份数量，下同）。 2、合计持有本公司股份 16,887,790 股（占本公司总股本比例 18.85%）的股 东珠海合晅投资中心（ ...

Group 1 - The core point of the announcement is that two major shareholders plan to reduce their holdings in the company through trading methods within a specified timeframe [1] Group 2 - Shareholder Enerjin Limited and its concerted parties plan to reduce their holdings by up to 888,300 shares, which represents 1% of the total share capital [1] - Shareholder Zhuhai Huanxian Investment Center and its concerted parties plan to reduce their holdings by up to 2,666,200 shares, which represents 3% of the total share capital [1] - The reason for the reduction in holdings is due to the shareholders' own financial arrangements [1]

Group 1 - The stock price of Ruimaite (301367.SZ) closed at 79.36 yuan, with a decline of 2.17%, currently below the issue price [1] - Yihe Jiaye was listed on the Shenzhen Stock Exchange's ChiNext on November 1, 2022, with a public offering of 16 million shares, accounting for 25% of the total share capital after issuance, at an issue price of 119.88 yuan per share [1] - The total amount raised by Yihe Jiaye was 191.808 million yuan, with a net amount of 173.82674 million yuan, exceeding the originally planned fundraising by 100.02698 million yuan [1] - The original fundraising plan was 73.79976 million yuan, intended for projects including the production of 300,000 ventilators and 3.5 million sets of accessories, marketing network and brand building, medical equipment R&D center, and working capital [1] - The underwriting institution for Yihe Jiaye was China International Capital Corporation (CICC), with representatives Chen Tingting and Xie Xianming [1] - The total issuance expenses amounted to 18.30202 million yuan, including underwriting and sponsorship fees of 15.71582 million yuan [1] - On May 22, 2024, Yihe Jiaye announced a dividend plan of 10 yuan (pre-tax) per 10 shares, with a bonus issue of 4 shares, with the ex-dividend date set for May 29, 2024 [1] Group 2 - On May 21, 2025, Yihe Jiaye announced a change of company name and stock abbreviation, changing from "Beijing Yihe Jiaye Medical Technology Co., Ltd." to "Beijing Ruimaite Medical Technology Co., Ltd." while the stock code "301367" remains unchanged [2]

Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2] Core Viewpoints - The innovation drug theme continues to gain momentum, with investment opportunities in traditional Chinese medicine innovation drug development companies [5][14] - The innovation drug sector has seen a significant recovery in stock prices due to accumulated industry advancements and improved funding conditions, leading to increased public fund allocations [5][14] - Short-term fluctuations are expected, but a positive outlook for the innovation drug market is maintained over the next 2-3 years, driven by overseas expansion and favorable funding conditions [6][14] Weekly Performance Summary - The pharmaceutical and biotechnology sector rose by 1.4%, outperforming the CSI 300 index by 1.66 percentage points, ranking 5th among 31 sub-industries [7][22] - The medical research outsourcing sector had the highest increase at 4.76%, while the vaccine sector saw the largest decline at 3.34% [7][22] Recommended and Beneficiary Stocks - Recommended stocks include: Yingke Medical, Maipu Medical, Yihe Jiaye, Weidian Shengli, Gongdong Medical, Pilin Bio, Yifeng Pharmacy, Daclin Pharmacy, Kangchen Pharmaceutical, Zoli Pharmaceutical, Guilin Sanjin, Tianshi Li, Xinlicheng, Meinian Health, and International Medicine [8][30] - Beneficiary stocks include: Shanwaishan, Yirui Technology, United Imaging, MicroPort, Junzheng Technology, BGI Genomics, Mindray Medical, Aohua Endoscopy, Linuo Pharmaceutical, Xinmai Medical, Kefu Medical, Zhonghong Medical, Runda Medical, Shengxiang Bio, BGI Genomics, Berry Genomics, Kingmed Diagnostics, Jiuan Medical, Wanfu Biology, Tiantan Biology, Aier Eye Hospital, Gushengtang, Jinxin Reproductive, Global Medical, Fangsheng Pharmaceutical, Guizhou Sanli, WuXi AppTec, Kanglong Chemical, Kylin Biopharma, and Nuotai Bio [8][30] Subsector Insights - The medical device sector is expected to benefit from the "old-for-new" policy and is projected to see significant growth starting in Q2 2025 [26] - The IVD sector is under pressure but has potential for recovery through AI-assisted diagnostics and new data services [31] - The blood products sector is experiencing a stable demand for albumin and immunoglobulin, with a focus on companies with strong operational efficiency [32] - The offline pharmacy sector is undergoing consolidation, with leading pharmacies expected to benefit from improved customer flow and profitability [35] - The traditional Chinese medicine sector is anticipated to recover as the impact of previous policies diminishes, with a focus on high-quality OTC products [39]

Group 1 - The project led by Tianjin Yihejiaye Medical Technology Co., Ltd. won the first prize of Tianjin Science and Technology Progress Award for the research and clinical application of non-invasive respiratory system key technologies [1] - Respiratory diseases have become the third largest chronic disease in China, following cardiovascular diseases and diabetes, with chronic obstructive pulmonary disease and obstructive sleep apnea being the most typical [1] - The non-invasive ventilator is currently the most effective medical device for treating respiratory diseases, with significant technological barriers existing in China compared to developed countries [1] Group 2 - The project achieved breakthroughs in core technologies, key equipment, system platforms, and international standards, possessing complete independent intellectual property rights [1] - A multi-center randomized controlled study was conducted in collaboration with 30 hospitals, focusing on the impact of high-intensity and low-intensity non-invasive positive pressure ventilation on the need for intubation in patients with acute exacerbations of chronic obstructive pulmonary disease [1] - The research results will be published in the Journal of the American Medical Association in 2024 [1] Group 3 - The project team also made advancements in the respiratory chronic disease management system, creating a respiratory data management cloud platform based on data from over 300,000 active users of non-invasive respiratory therapy [2] - The cloud platform connects patients, their families, and doctors, allowing real-time monitoring of sleep-related respiratory data and enabling remote adjustment of treatment parameters by doctors [2] - In 2023, the global market share of Ruimai Te's home non-invasive ventilator was 12.4%, ranking second, while its domestic market share was 30.6%, ranking first among domestic brands [2] Group 4 - As of January 2025, the cumulative sales of Ruimai Te's home ventilators exceeded 3 million units, and the cumulative sales of ventilation masks surpassed 10 million units [2]

Company Overview - Beijing RMT Medical Technology Co., Ltd. was established in 2001 and successfully listed on the Shenzhen Stock Exchange's Growth Enterprise Market on November 1, 2022 [2] - The company specializes in providing comprehensive treatment solutions for OSA and COPD patients, focusing on home non-invasive ventilators and ventilation masks [2] - RMT is the first domestic company to have non-invasive ventilator products certified by the FDA, with sales in over 100 countries [2] Research and Development - As of December 31, 2024, the company holds 633 valid patents in China, including 107 invention patents, 390 utility model patents, and 136 design patents [3] - The company also has 202 valid overseas patents, including 39 in the United States and 30 in Europe [3] Financial Performance - In Q1 2025, the company's overseas revenue reached 170 million CNY, a year-on-year increase of 35.48%, while domestic revenue was 96 million CNY, with a quarter-on-quarter growth of 48.79% and a year-on-year growth of 43.03% [4] - The gross margin for domestic operations was 51.51%, and for overseas operations, it was 48.47%, with both showing an increase compared to the previous quarter [4] Product Launches and Market Strategy - The newly launched P5 series ventilators are primarily targeted at domestic hospital channels, which have a relatively high gross margin [4] - The introduction of the RMT oxygen bottle marks a strategic shift towards the consumer goods market, enhancing brand influence and market share [5] Brand Development - The company's rebranding to "RMT" signifies a strategic alignment between product and capital markets, aiming to enhance brand value [5] - The name "RMT" reflects the company's commitment to respiratory health and smart technology, creating a unified identity across products and capital markets [5] Market Expansion - The company has made adjustments to domestic channel policies and sales strategies, resulting in improved revenue and gross margins in Q1 2025 [5] - In Europe, the company has completed the construction of its cloud platform and is onboarding agents, laying the groundwork for future growth in the mainstream medical insurance market [5]

Core Viewpoint - In May 2025, over 70% of the 8,451 comparable mixed funds experienced net value increases, indicating a positive trend in the market [1] Fund Performance Summary - A total of 54 mixed funds achieved a monthly increase of over 10%, with Jinxin Value Selected Mixed A and C leading at 19.38% and 19.36% respectively [2] - Jinxin Value Selected Mixed A and C, established on September 1, 2017, reported year-to-date returns of 32.65% and 32.60%, and cumulative returns of 48.85% and 49.57% as of May 30, 2025 [2] - The top ten holdings of Jinxin Value Selected Mixed A and C focus on the pharmaceutical and biotechnology sectors, particularly in innovative industries [2] - Huabao Pharmaceutical and Biological Mixed A achieved a monthly increase of 11.49%, with a year-to-date return of 41.55% and a cumulative return of 381.22% since its inception [3] Fund Decline Summary - 15 mixed funds saw declines exceeding 10% in May, with Furong Fuxin Mixed C and A at the bottom with -12.39% and -12.38% respectively [4] - Furong Fuxin Mixed C and A focus on humanoid robotics, with their top holdings including Huachen Equipment and Qinchuan Machine Tool [4] Fund Manager Insights - The current fund manager for Jinxin Value Selected Mixed A and C is Zhao Haoran, who has a background in financial research and joined Jinxin Fund in August 2022 [2] - Huabao Pharmaceutical and Biological Mixed A is managed by Zhang Jintao, who has extensive experience in investment research across various financial institutions [3] - Furong Fuxin Mixed C and A are co-managed by Li Yanzheng and Mao Yunhong, both of whom have significant experience in research and fund management [4]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2] Core Viewpoints - The report emphasizes that the ASCO conference has catalyzed enthusiasm for innovative drug investments, with a notable increase in the number of presentations by Chinese experts [3][12] - It is believed that innovative drugs will remain the main focus of pharmaceutical investments in the medium to long term, driven by China's transition from quantity to quality and innovation in drug development, alongside increasing policy support [3][12] - Short-term factors such as US-China tariff disputes and geopolitical tensions may affect overall risk appetite, suggesting a focus on companies that can commercialize large-scale innovative drugs and those in the CXO and life sciences upstream sectors [3][12] Summary by Sections Market Performance - The pharmaceutical and biotechnology sector's weekly return was 2.21%, outperforming the CSI 300 by 3.30%, ranking second among 31 primary sub-industry indices [10] - The chemical pharmaceuticals sub-sector led with a weekly return of 3.83% [10][27] - Over the past month, the sector's return was 6.42%, again ranking second among sub-industry indices [10][17] Industry Dynamics - The report highlights the importance of the ASCO conference held from May 30 to June 3, 2025, in Chicago, which has further stimulated investment interest in innovative drugs [11][12] - The report suggests focusing on the CXO and life sciences upstream sectors, as well as traditional pharmaceutical companies transitioning from generics to innovative drugs [13][14] Recommendations - Companies to watch in the innovative drug chain include Tigermed, WuXi AppTec, and others in the CRO/CDMO space [13] - For the domestic recovery line, companies like Aier Eye Hospital and Tongrentang are recommended [13] - In the self-sufficiency line, high-end medical devices and research instruments from companies like Mindray and Hualan Biological Engineering are highlighted [14] Company-Specific Insights - The report identifies specific companies with strong growth potential, such as Yaoshi Bang, which is expected to achieve a CAGR of approximately 145% in net profit from 2024 to 2027 [15] - Kangchen Pharmaceutical has maintained a net profit growth rate of over 14% for the past three years, with a projected PE of about 8 times in 2025 [15] - Guoyuyuan is expected to see operational improvements in 2025, marking a potential turning point for the company [15][16]

Core Viewpoint - The company has shown a recovery in performance with Q1 2025 results exceeding expectations, driven by improved order fulfillment in the U.S. market and ongoing domestic growth initiatives [1][3][10] Financial Performance - For 2024, the company reported revenue of 843 million yuan (down 24.85%), net profit attributable to shareholders of 155 million yuan (down 47.74%), and net profit excluding non-recurring items of 92 million yuan (down 61.79%) [2][3] - In Q1 2025, revenue reached 265 million yuan (up 38.11%), net profit attributable to shareholders was 72 million yuan (up 44.11%), and net profit excluding non-recurring items was 60 million yuan (up 43.18%) [2][4] Market Outlook - The company anticipates continued growth in Q2 2025, particularly in the U.S. market, as the low base effect from the previous year supports performance [1][5] - The company plans to enhance brand promotion and channel development in both domestic and international markets throughout the year [1][5][10] Business Segmentation - Revenue from home respiratory therapy products in 2024 was 527 million yuan (down 38.15%), while consumables revenue was 284 million yuan (up 46.22%) [4] - In Q1 2025, home respiratory therapy revenue was 176 million yuan (up 62.80%), and consumables revenue was 81 million yuan (up 7.46%) [4][9] Brand Development - The company changed its name from "怡和嘉业" to "瑞迈特" on May 21, aiming to enhance brand influence and align its corporate identity with its core product offerings [2][5][6] R&D and Innovation - The company is committed to maintaining high levels of R&D investment to improve product performance and expand market share [1][5][10] - Future innovations in respiratory products are expected to leverage AI and brain-machine interface technologies for enhanced functionality [6] Incentive Plans - The company announced a stock incentive plan for 2025, aiming to grant up to 704,000 restricted shares to 54 key personnel, with performance targets set for revenue growth [7]

Group 1: Company Overview - Beijing Ruimait Medical Technology Co., Ltd. was established in 2001 and launched its first multi-channel sleep monitor in 2003, followed by the first CPAP sleep machine in 2007 [2] - The company focuses on providing comprehensive treatment solutions for OSA and COPD patients, covering diagnosis, treatment, and chronic disease management [2] - Ruimait is a leading domestic company in non-invasive ventilators and masks, being the first domestic company to receive FDA certification for non-invasive ventilators [2][3] Group 2: Market Position and Performance - As of 2023, Ruimait holds a 30.6% market share in the domestic market for home non-invasive ventilators, ranking first, and a 12.4% share globally, ranking second [4] - The company has established a comprehensive product line, including home non-invasive ventilators, masks, sleep monitors, high-flow humidified oxygen therapy devices, and oxygen concentrators [2][3] Group 3: Research and Development - As of December 31, 2024, the company holds 633 valid patents in China, including 107 invention patents, 390 utility model patents, and 136 design patents [3] - The company also has 202 valid overseas patents, including 39 in the United States and 30 in Europe [3] Group 4: Strategic Initiatives - The recent rebranding to "Ruimait" aims to unify product identity and capital market recognition, enhancing brand value and market penetration [5] - A strategic partnership with Shenzhen Hanyu Pharmaceutical Co., Ltd. focuses on joint development of respiratory machines and health products, targeting mild sleep disorder consumers [6] - The company is exploring collaboration with Qiangnao Technology, a leader in non-invasive brain-machine interfaces, to enhance product functionality [7] Group 5: Financial Performance and Market Strategy - In Q1 2025, the company reported an increase in domestic business revenue and gross margin, indicating a stable market performance [8] - The launch of the Ruimait oxygen bottle signifies a strategic shift towards consumer products, aiming to enhance brand influence and market share [10]